AHA 2021 – Bristol touts its Eliquis follow-on
Phase 2 data with milvexian look good, but Eliquis will be a hard act to follow.
SITC 2021 – Incyte unveils its oral checkpoint blocker
There are some remissions, but peripheral neuropathy casts a long shadow.
The quest for efficacy in pancreatic cancer
Late-stage therapies from Fibrogen, Tyme and Novartis need to avoid the same pitfalls as Erytech and Rafael.
SITC 2021 – ALX Oncology's unpleasant double dip
Evorpacept adds a solid tumour setback to last week’s disappointment in blood cancers, and the CD47 bubble deflates.
Ash 2021 preview – as competition grows Autolus monetises
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
TCT 2021 – Medtronic and Edwards target hard-to-reach valves
Transcatheter technologies could be the future – but a distant one.
Esmo IO 2021 – Propel fails to propel Nektar
The focus now falls on first-line melanoma data with bempegaldesleukin plus Opdivo, due in early 2022.
Ash 2021 preview – small increases and big falls
The early movers could point to a disappointing meeting.
RSVVW 2021 – Pfizer gets maternal
Positive phase 2 data with the group’s maternal RSV vaccine set up a busy 2022 for work on the infectious disease.
